Cephalon Drops Patent Suit Vs. Sandoz Over Provigil

Law360, New York (May 3, 2005, 12:00 AM EDT) -- Cephalon, Inc. has dropped its patent infringement suit against Swiss drug maker Sandoz following that drugmaker's decision not to market a generic version of Cephalon's drug Provigil.

According to Cephalon, Sandoz has decided not to challenge Cephalon's patent position on Provigil, a treatment for excessive day-time sleepiness. Instead, Sandoz will wait until 2014 to seek to put out a generic version of the drug, when a patent on one of Provigil's key ingredients is set to expire.

Instead, Sandoz plans to convert its abbreviated new drug...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.